Filing Details

Accession Number:
0001209191-23-032391
Form Type:
4
Zero Holdings:
No
Publication Time:
2023-05-26 11:31:59
Reporting Period:
2023-05-24
Accepted Time:
2023-05-26 11:31:59
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1160308 Savara Inc SVRA Pharmaceutical Preparations (2834) 841318182
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1283292 A David Ramsay 6836 Bee Cave Road
Building I, Suite 205
Austin TX 78746
Yes No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2023-05-24 50,000 $2.56 2,151,142 No 4 P Direct
Common Stock Acquisiton 2023-05-25 12,876 $2.57 2,164,018 No 4 P Direct
Common Stock Acquisiton 2023-05-26 37,124 $2.63 2,201,142 No 4 P Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Direct
No 4 P Direct
No 4 P Direct
Footnotes
  1. The price is a weighted average purchase price. The purchase prices ranged from $2.54 to $2.57. The reporting person undertakes to provide Savara Inc., any security holder of Savara Inc., or the staff of the Securities and Exchange Commission, upon receipt of a request, full information regarding the number of shares purchased at each separate price within the range set forth in this Form 4.
  2. The price is a weighted average purchase price. The purchase prices ranged from $2.55 to $2.59. The reporting person undertakes to provide Savara Inc., any security holder of Savara Inc., or the staff of the Securities and Exchange Commission, upon receipt of a request, full information regarding the number of shares purchased at each separate price within the range set forth in this Form 4.
  3. The price is a weighted average purchase price. The purchase prices ranged from $2.60 to $2.66. The reporting person undertakes to provide Savara Inc., any security holder of Savara Inc., or the staff of the Securities and Exchange Commission, upon receipt of a request, full information regarding the number of shares purchased at each separate price within the range set forth in this Form 4.